Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Neurofibromin (NF1) is a key negative regulator of RAS signaling, and its mutation is common in cancers.
• NF1-mutant melanoma is an aggressive cancer with limited targeted therapy options.

Purpose of the Study:

• To identify pharmacologic targets for NF1-mutant melanoma.
• To investigate the role of RAS-MAPK pathway in NF1-deficient melanomas.
• To evaluate combination therapies involving MEK and SOS1 inhibition.

Main Methods:

• Biochemical and pharmacological assays.
• Utilized patient-derived models and isogenic cell lines.
• Investigated RAS-MAPK pathway signaling dynamics.

Main Results:

• NF1-null melanomas exhibit dependency on RAS activation.
• MEK inhibition alone has limited antitumor effects due to adaptive ERK signaling rebound.
• Concurrent MEK and SOS1 inhibition abrogates ERK activation, induces cell death, and suppresses tumor growth in NF1-null models.
• NF1 wild-type cells require combined SOS1 and SOS2 inhibition to fully block RAS signaling.

Conclusions:

• The study provides a mechanistic rationale for combining MEK inhibitors with SOS1 inhibitors in NF1-mutant melanoma.
• Exploiting lower residual SOS activity in NF1-null tumors can enhance therapeutic efficacy.
• This combination strategy offers a promising avenue for treating aggressive NF1-mutant melanomas.